Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox

Tonix Pharmaceuticals Holding Corp. announced that it received the official written response from a Type B pre-Investigational New Drug Application meeting with the US FDA to develop TNX-8011 as a potential vaccine to protect against mpox disease and smallpox.